Patient | Age/sex | HRCT pattern | Year of ILD diagnosis | Serum auto-antibody/CTD features | Pre-rituximab immunosuppression |
Polymyositis/dermatomyositis | |||||
1 | 45/M | Organising pneumonia/DAD | 2009 | ENA, anti-Ro positive DM on muscle biopsy | i.v. methylprednisolone |
2 | 60/M | Fibrotic NSIP* | 2003 | Anti-Jo 1, myositis | MMF, prednisolone, cyclosporine i.v. cyclophosphamide |
3 | 60/F | Fibrotic NSIP | 2000 | Anti-Jo 1, myositis rheumatoid factor | MMF, prednisolone i.v. cyclophosphamide |
4 | 29/F | Fibrotic NSIP | 2009 | Anti-Jo 1, myositis anti-Ro | MMF, prednisolone i.v. cyclophosphamide |
5 | 51/M | Fibrotic NSIP | 2005 | Anti-Jo 1, myositis | MMF, prednisolone i.v. cyclophosphamide |
Undifferentiated CTD | |||||
6 | 49/M | Fibrotic NSIP | 2006 | ANA +++ (speckled) Raynaud's, GORD | i.v. cyclophosphamide prednisolone, MMF |
7 | 37/F | Organising pneumonia/DAD | 2009 | Rheumatoid factor anti-CCP, anti-Ro | i.v. methylprednisolone |
Systemic sclerosis | |||||
8 | 63/M | Fibrotic NSIP | 1999 | ATA | MMF, prednisolone |
HRCT: high-resolution computed tomography; ILD: interstitial lung disease; CTD: connective tissue disease; M: male; F: female; DAD: diffuse alveolar damage; ENA: extractable nuclear antigen; DM: dermatomyositis; NSIP: non-specific interstitial pneumonia; MMF: mycophenolate mofetil; ANA: anti-nuclear antibody; GORD: gastro-oesophageal reflux disease; CCP: cyclic citrullinated peptide; ATA: anti-topoisomerase antibody. *: fibrotic NSIP confirmed on surgical lung biopsy.